June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Changes in axial length and subfoveal choroidal thickness after photodynamic therapy for central serous chorioretinopathy
Author Affiliations & Notes
  • Nobuhiro Terao
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto Kamigyo-ku, Japan
  • Tetsuya Yamagishi
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto Kamigyo-ku, Japan
  • Yuji Yamamoto
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto Kamigyo-ku, Japan
  • Hideki Koizumi
    Ophthalmology, Department of Ophthalmology Tokyo Women's Medical University, Tokyo, Japan
  • Chie Sotozono
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto Kamigyo-ku, Japan
  • Footnotes
    Commercial Relationships   Nobuhiro Terao, None; Tetsuya Yamagishi, None; Yuji Yamamoto, None; Hideki Koizumi, None; Chie Sotozono, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5928. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nobuhiro Terao, Tetsuya Yamagishi, Yuji Yamamoto, Hideki Koizumi, Chie Sotozono; Changes in axial length and subfoveal choroidal thickness after photodynamic therapy for central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5928.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the changes in axial length (AL) and subfoveal choroidal thickness (SCT) after half-dose verteporfin photodynamic therapy (PDT) for central serous chorioretinopathy (CSC).

Methods : This retrospective, observational case series involved 48 eyes (24 CSC eyes and 24 unaffected fellow eyes) of 24 patients (4 females and 20 males; mean age: 55.0+/-10.5 years) with unilateral CSC which showed the disappearance of serous retinal detachment after PDT. CSC was diagnosed using optical coherence tomography (OCT), fluorescein angiography, and indocyanine green angiography. The primary outcomes were the changes before and at 3-months after PDT in AL, SCT and spherical equivalent (SE) in the treated eyes and those in the unaffected fellow eyes. SCT was measured on enhanced depth imaging-OCT (EDI-OCT) images and AL was measured via partial coherence interferometry (IOLMaster; Carl Zeiss Meditec).

Results : The mean AL in the treated eyes increased significantly from 23.85+/-1.11mm at baseline to 24.01+/-1.13mm (P<0.001) at 3-months after PDT, whereas that in the unaffected eyes changed from 24.06+/-1.16mm at baseline to 24.05+/-1.16mm at 3-months after PDT (P=0.118). The mean SCT in the treated eyes decreased significantly from 462+/-70μm at baseline to 391+/-90μm (P<0.001) at 3-months after PDT, whereas that in the unaffected eyes changed from 363+/-95μm at baseline to 366+/-96μm (P=0.479). In the treated eyes, significant elongation of AL (mean change: 0.16+/-0.13mm=160μm; P<0.001; 95%CI: 0.11-0.21) and significant reduction of SCT (mean change: 71+/-44μm; P<0.001; 95%CI: 52-90) were observed at 3-months after PDT. No difference was found at baseline and at 3-months after PDT in regard to SE in both the treated eyes and the unaffected fellow eyes.

Conclusions : A distinct difference was found between the elongation of AL and the reduction of SCT after PDT in the treated eyes. This finding suggests that PDT may have a secondary morphological change in tissues (i.e., suprachoroidal space or sclera) other than choroid. During the active phase of CSC, the excessive fluid may pool in the submacular suprachoroidal space in association with the impaired choroidal outflow induced by the scleral thickening.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×